NCT03133741

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: Male
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.

Detailed description

Aim: To evaluate the role of GIPR signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring GIP fragment (GIP-A), which antagonises the GIPR. Eighteen healthy men (age 18-70 years, BMI 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin\[9-39\], C) GIP-A + Exendin\[9-39\], or D) saline (placebo).

Conditions

• Glucose Metabolism Disorders

Interventions

Type	Name	Description
OTHER	GIP-A	GIP-A (GIP receptor antagonist)
OTHER	GLP-1 receptor antagonist Exendin[9-39]	Exendin\[9-39\]
OTHER	Placebo	Saline (9mg/mL)
OTHER	GIP-A + Exendin[9-39]	GIP receptor antagonist + GLP-1 receptor antagonist

Timeline

• Start date: 2017-03-01
• Primary completion: 2017-07-01
• Completion: 2017-07-01
• First posted: 2017-04-28
• Last updated: 2017-11-01

Locations

1 site across 1 country: Denmark